1. PRIMARY HORIZON SCANNING
All treatments with international trials
All anti-virals, anti-inflammatory/immunomodulatory, cell-based therapies and other treatments
NIHR

2. INITIAL STRATIFICATION
Scoring applied against agreed criteria* to order longlist for priority consideration
NIHR

3. ENRICHMENT
Review of NIHRIO outputs, gathering and addition of intelligence from sponsors and other sources, and interpretation to identify priority candidates for consideration by the RAPID-C19 Oversight Group
NICE

4. SCHEDULING
Priority candidates are scheduled for briefing, Rapid Action Plan development and review by RAPID-C19 OG
NICE

5. BRIEFING & RAPID ACTION PLAN (RAP) DEVELOPMENT
Briefing notes with suggested RAP actions plans on priority candidates compiled to inform Rapid C19 Oversight Group recommendations
NICE

RAPID-C19 OVERSIGHT GROUP REVIEW
NICE/NIHR/MHRA/NHSE

Timing:
May depend on regulatory tool/approach chosen. Rapid EAMS suggested 10 days

RAPID REGULATORY SIGNAL PROCESS
MHRA

APPLICATION OF REGULATORY SIGNAL TO PATIENT ACCESS
NHSE

HTA
NICE

Subsequent timing: TBC

LICENSING
MHRA

Primary horizon scanning updated daily
Initial stratification updated 2x weekly

Includes latest trial information NIHR

Enrichment to briefing & RAP - rolling weekly cycle

Criteria agreed by partner organisations

Not ready - further monitoring / information required

Trial signal indicating readiness to progress

e.g. Interim commissioning policy